Analysts are on the Bearish side about Kamada Ltd. (NASDAQ:KMDA) this week.

April 17, 2018 - By Ellis Scott

Kamada Ltd. (NASDAQ:KMDA) Ratings Coverage

Among 2 analysts covering Kamada (NASDAQ:KMDA), 2 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Kamada had 2 analyst reports since February 2, 2018 according to SRatingsIntel. The firm earned “Buy” rating on Thursday, February 8 by H.C. Wainwright. Below is a list of Kamada Ltd. (NASDAQ:KMDA) latest ratings and price target changes.

08/02/2018 Broker: H.C. Wainwright Rating: Buy New Target: $11.0 Maintain
02/02/2018 Broker: Chardan Capital Markets Rating: Buy New Target: $7 Initiates Coverage On

The stock increased 1.09% or $0.05 during the last trading session, reaching $4.65. About 12,350 shares traded. Kamada Ltd. (NASDAQ:KMDA) has declined 31.39% since April 17, 2017 and is downtrending. It has underperformed by 42.94% the S&P500.

Kamada Ltd. develops, produces, and markets specialty plasma-derived protein therapeutics. The company has market cap of $187.90 million. It operates through two divisions, Proprietary Products and Distribution. It has a 25.83 P/E ratio. The companyÂ’s respiratory products include Glassia for use in augmentation and maintenance therapy in adults with emphysema due to congenital AAT deficiency ; Bramitob to manage chronic pulmonary infection; and FOSTER for the treatment of asthma.

Kamada Ltd. (NASDAQ:KMDA) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: